Cargando…
Pharmacological treatments of presbyopia: a review of modern perspectives
INTRODUCTION: Presbyopia affects people from the 4(th) decade of life and is characterized by accommodative loss that leads to negative effects on vision-targeted health-related quality of life. A non-invasive pharmacological treatment providing near-lenses independence would be a truly groundbreaki...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294898/ https://www.ncbi.nlm.nih.gov/pubmed/28191476 http://dx.doi.org/10.1186/s40662-017-0068-8 |
_version_ | 1782505328582066176 |
---|---|
author | Renna, Antonio Alió, Jorge Luciano Vejarano, Luis Felipe |
author_facet | Renna, Antonio Alió, Jorge Luciano Vejarano, Luis Felipe |
author_sort | Renna, Antonio |
collection | PubMed |
description | INTRODUCTION: Presbyopia affects people from the 4(th) decade of life and is characterized by accommodative loss that leads to negative effects on vision-targeted health-related quality of life. A non-invasive pharmacological treatment providing near-lenses independence would be a truly groundbreaking approach in the treatment of presbyopia. The purpose of this review is to analyze the emerging pharmacological solutions proposed to address presbyopia. RESULTS: Several ophthalmic eye drops compounds solutions have been described in peer-reviewed papers or presented in ophthalmological tabloids and congresses. Each topical treatment deals with drug combinations aimed to modify one or more factors involved in the accommodative process and have been proposed to be instilled either monocularly or binocularly. It remains unclear how much each drug in the final combined form is involved in the achievement of the outcome and contributes to it. CONCLUSION: Despite the lack of a completely well understood mechanism, pharmacological control of presbyopia seems to be a possible and very attractive alternative for presbyopic patients. The studies mentioned in this review are to be considered pilot investigations as they involve either a small number of subjects or are single case series. Complete studies are needed to confirm which will be the more effective pharmacological compound for the treatment of presbyopia. |
format | Online Article Text |
id | pubmed-5294898 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-52948982017-02-10 Pharmacological treatments of presbyopia: a review of modern perspectives Renna, Antonio Alió, Jorge Luciano Vejarano, Luis Felipe Eye Vis (Lond) Review INTRODUCTION: Presbyopia affects people from the 4(th) decade of life and is characterized by accommodative loss that leads to negative effects on vision-targeted health-related quality of life. A non-invasive pharmacological treatment providing near-lenses independence would be a truly groundbreaking approach in the treatment of presbyopia. The purpose of this review is to analyze the emerging pharmacological solutions proposed to address presbyopia. RESULTS: Several ophthalmic eye drops compounds solutions have been described in peer-reviewed papers or presented in ophthalmological tabloids and congresses. Each topical treatment deals with drug combinations aimed to modify one or more factors involved in the accommodative process and have been proposed to be instilled either monocularly or binocularly. It remains unclear how much each drug in the final combined form is involved in the achievement of the outcome and contributes to it. CONCLUSION: Despite the lack of a completely well understood mechanism, pharmacological control of presbyopia seems to be a possible and very attractive alternative for presbyopic patients. The studies mentioned in this review are to be considered pilot investigations as they involve either a small number of subjects or are single case series. Complete studies are needed to confirm which will be the more effective pharmacological compound for the treatment of presbyopia. BioMed Central 2017-02-07 /pmc/articles/PMC5294898/ /pubmed/28191476 http://dx.doi.org/10.1186/s40662-017-0068-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Renna, Antonio Alió, Jorge Luciano Vejarano, Luis Felipe Pharmacological treatments of presbyopia: a review of modern perspectives |
title | Pharmacological treatments of presbyopia: a review of modern perspectives |
title_full | Pharmacological treatments of presbyopia: a review of modern perspectives |
title_fullStr | Pharmacological treatments of presbyopia: a review of modern perspectives |
title_full_unstemmed | Pharmacological treatments of presbyopia: a review of modern perspectives |
title_short | Pharmacological treatments of presbyopia: a review of modern perspectives |
title_sort | pharmacological treatments of presbyopia: a review of modern perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294898/ https://www.ncbi.nlm.nih.gov/pubmed/28191476 http://dx.doi.org/10.1186/s40662-017-0068-8 |
work_keys_str_mv | AT rennaantonio pharmacologicaltreatmentsofpresbyopiaareviewofmodernperspectives AT aliojorgeluciano pharmacologicaltreatmentsofpresbyopiaareviewofmodernperspectives AT vejaranoluisfelipe pharmacologicaltreatmentsofpresbyopiaareviewofmodernperspectives |